

Comparative Monolithic (Single Layer)
Tablet
= Cobicistat
= Atazanavir Sulfate

FIG. 1



Total Cobi Impurity
Impurity %
4.00
3.50
3.00
2.50
2.00
1.50
1.00
0.50
0.00
0
2
4
6
8
10
Time point (week)
Monolithic FDC 40C/75%RH
Bilayer 40C/75%RH closed 200cc
Trilayer 40C/75%RH
Cobi Tablet 40C/75%RH

FIG. 2



Oxidative and Hydrolytic Degradation Pathways of COBI
BMT-111069
Isomer
+
BMT-111068
Isomer
Dehydration
GS-465430
Oxidative
Oxidative
Oxidative
Oxidative
Cobicistat
BMT-089280
Conformer
Hydrolytic
Hydrolytic
GS-9612
BMT-115982
GS-9454
GS-445739
GS-344433
GS-9398

FIG. 3



Comparative Trilayer Tablet
Inert
Middle
Layer
= Cobicistat
= Atazanavir Sulfate

FIG. 4




FIG. 5



Total Impurity (Cobicistat) Results for ATV/COBI FCT, 300 mg as Free Base/150 mg, Stored at Long-Term Conditions
Total Impurities (Known and Unknown) %
2
1.8
1.6
1.4
1.2
1
0.8
0.6
0.4
0.2
0
0
5
10
15
Months
Batch #
2J73498, 25°C/ 60% RH
2J73498, 30°C/ 75% RH
2J73498, 5°C
2J73499, 25°C/ 60% RH
2J73499, 30°C/ 75% RH
2J73499, 5°C
2J73500, 25°C/ 60% RH
2J73500, 30°C/ 75% RH
2J73500, 5°C

FIG. 6